Join the Mission Bio team at the 64th ASH Annual Meeting and Exposition on December 10-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Booth #2014). Our Chief Medical Officer, Todd Druley, Business Development, and Translational Applications Liaison teams will be on-site and available to answer any questions you might have about single-cell DNA sequencing and the Tapestri workflow.
If you are attending and would like to schedule some one-on-one time with our team to learn more, please fill out the form and we'll be in contact shortly.
Saturday, December 10, 2022
"Integrative Analysis of Blast Phase Chronic Myelomonocytic Leukemia Reveals Distinct Transformation Phenotypes Predictive of Drug Response." K. Gurashi, University of Manchester, UK. 10am CT.
"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications." H. Döhner, Servier Pharmaceuticals. 2pm CT.
"Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis." Bridget K Marcellino, Icahn School of Medicine Mount Sinai. 4:30pm CT.
"Identification of PTPN11 mutations as Early Events in the Development of Acute Myeloid Leukemia." S. Fobare, Ohio State University Comprehensive Cancer Center. 5pm CT.
Sunday, December 11, 2022
"Germline SAMD9/9L MDS Predisposition Syndromes Are Characterized By Complex Clonal Architecture and Lineage-Specific Escape Mechanisms Including Somatic Genetic Rescue in T and B Lymphocytes." Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital. 9:45am CT.
"Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis." Caner Saygin, MD, University of Chicago. 10:30am CT.
"AML single-cell multi-omics MRD (scMRD) and the horizon of clinical utility." Aaron Llanso, Mission Bio company showcase. 4pm CT.
Monday, December 12, 2022
"Multi-omic Single-cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients with FLT-3-Mutated AML Treated with Gilteritinib/Venetoclax." V. E. Kennedy, University of California San Francisco. 5pm CT.
"Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia." T. Robinson, Memorial Sloan Kettering Cancer Center. 5:30pm CT.
Saturday, December 10 | 5:30-7:30pm CT | Hall D
"Utilization of the Tapestri Platform for Quantification of Single Cell Vector Copy Number in CAR T Cell Products." L. Murphy, University of Colorado Anschutz Medical Campus.
"Clonal Architecture and Evolution of Waldenström’s Macroglobulinemia at the Single Cell Level." C. Jiménez, University Hospital of Salamanca.
"Decreased Embryonic Splicing Repressor Expression Enhances Splicing Modulator Sensitivity in Pediatric Acute Myeloid Leukemia Stem Cells." I. Van Der Werf, Amsterdam University Medical Center.
"Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling." L. Balaian, Moores Cancer Center and Sanford Stem Cell Clinical Center.
Sunday, December 11 | 6:00-8:00pm CT | Hall D
"Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7." T. Westover, St. Jude's Children's Research Hospital.
"Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML." G.C. Issa, MD Anderson Cancer Center.
Monday, December 12 | 6:00-8:00pm CT | Hall D
"Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity." V.E. Kennedy, University of California San Francisco.